Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

NCT02933944 is registered in ClinicalTrials.gov with Targovax ASA as lead sponsor.

NCT NCT02933944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02933944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
Lead sponsor
Targovax ASA
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2016
Completion date
September 30, 2019
Enrollment
6 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer